Calculating the predicted retinal thickness from spectral domain and time domain optical coherence tomography – comparison of different methods

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 9, 2014, Pages 1491-1499

  Tan, Colin S ^a,b   Li, Kelvin Z ^a   Lim, Tock Han ^a,b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL HEALTHCARE GROUP EYE INSTITUTE   (Singapore)

Author keywords

Central retinal thickness; Optical coherence tomography; Spectral domain OCT; Time domain OCT

Indexed keywords

ADULT; ANATOMY AND HISTOLOGY; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MALE; MIDDLE AGED; NORMAL HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; REPRODUCIBILITY; RETINA; VISUAL SYSTEM EXAMINATION; YOUNG ADULT;

ADULT; COHORT STUDIES; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; FALSE POSITIVE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; YOUNG ADULT;

EID: 84925224348     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2672-9     Document Type: Article

References (29)

1. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908
2. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL III (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398
3. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411
4. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583
5. Legarreta JE, Gregori G, Punjabi OS, Knighton RW, Lalwani GA, Puliafito CA (2008) Macular thickness measurements in normal eyes using spectral domain optical coherence tomography. Ophthalmic Surg Lasers Imaging 39:S43–S49
6. Tan CS, Ouyang Y, Ruiz H, Sadda SR (2012) Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 53:261–266
7. Tan CS, Cheong KX, Lim LW, Li KZ (2014) Topographic variation of choroidal and retinal thicknesses at the macula in healthy adults. Br J Ophthalmol 98:339–344
8. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, Enzmann V, Wolf S (2009) Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 50:3432–3437
9. Carpineto P, Nubile M, Toto L, Aharrh GA, Marcucci L, Mastropasqua L, Ciancaglini M (2010) Correlation in foveal thickness measurements between spectral-domain and time-domain optical coherence tomography in normal individuals. Eye (Lond) 24:251–258
10. Leung CK, Cheung CY, Weinreb RN, Lee G, Lin D, Pang CP, Lam DS (2008) Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 49:4893–4897
11. Menke MN, Dabov S, Sturm V (2009) Comparison of three different optical coherence tomography models for total macular thickness measurements in healthy controls. Ophthalmologica 223:352–356
12. Lammer J, Scholda C, Prunte C, Benesch T, Schmidt-Erfurth U, Bolz M (2011) Retinal thickness and volume measurements in diabetic macular edema: a comparison of four optical coherence tomography systems. Retina 31:48–55
13. Huang J, Liu X, Wu Z, Xiao H, Dustin L, Sadda S (2009) Macular thickness measurements in normal eyes with time-domain and Fourier-domain optical coherence tomography. Retina 29:980–987
14. Chopovska Y, Jaeger M, Rambow R, Lorenz B (2011) Comparison of central retinal thickness in healthy children and adults measured with the Heidelberg Spectralis OCT and the zeiss Stratus OCT 3. Ophthalmologica 225:27–36
15. Grover S, Murthy RK, Brar VS, Chalam KV (2010) Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci 51:2644–2647
16. Kakinoki M, Sawada O, Sawada T, Kawamura H, Ohji M (2009) Comparison of macular thickness between Cirrus HD-OCT and Stratus OCT. Ophthalmic Surg Lasers Imaging 40:135–140
17. Han IC, Jaffe GJ (2009) Comparison of spectral- and time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. Am J Ophthalmol 147(847–58):858
18. Giani A, Cigada M, Choudhry N, Deiro AP, Oldani M, Pellegrini M, Invernizzi A, Duca P, Miller JW, Staurenghi G (2010) Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol 150:815–824
19. Costa RA, Calucci D, Skaf M, Cardillo JA, Castro JC, Melo LA Jr, Martins MC, Kaiser PK (2004) Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 45:2399–2406
20. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT (2008) Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci 49:4290–4296
21. Pierro L, Giatsidis SM, Mantovani E, Gagliardi M (2010) Macular thickness interoperator and intraoperator reproducibility in healthy eyes using 7 optical coherence tomography instruments. Am J Ophthalmol 150:199–204
22. Tan CS, Li KZ, Lim TH (2012) A novel technique of adjusting segmentation boundary layers to achieve comparability of retinal thickness and volumes between spectral domain and time domain optical coherence tomography. Invest Ophthalmol Vis Sci 53:5515–5519
23. Heussen FM, Ouyang Y, McDonnell EC, Narala R, Ruiz-Garcia H, Walsh AC, Sadda SR (2012) Comparison of manually corrected retinal thickness measurements from multiple spectral-domain optical coherence tomography instruments. Br J Ophthalmol 96:380–385
24. Abedi G, Patal P, Doros G, Subramanian ML (2011) Transitioning from stratus OCT to cirrus OCT: a comparison and a proposed equation to convert central subfield macular thickness measurements in healthy subjects. Graefes Arch Clin Exp Ophthalmol 249:1353–1357
25. Ibrahim MA, Sepah YJ, Symons RC, Channa R, Hatef E, Khwaja A, Bittencourt M, Heo J, Do DV, Nguyen QD (2012) Spectral and time-domain optical coherence tomography measurements of macular thickness in normal eyes and in eyes with diabetic macular edema. Eye (Lond) 26:454–462
26. Forte R, Cennamo GL, Finelli ML, de Crecchio G (2009) Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye (Lond) 23:2071–2078
27. Tan CS, Li KZ (2013) Equations to calculate central subfield thickness on optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 251:409–410
28. Comyn O, Heng LZ, Ikeji F, Bibi K, Hykin PG, Bainbridge JW, Patel PJ (2012) Repeatability of Spectralis OCT measurements of macular thickness and volume in diabetic macular edema. Invest Ophthalmol Vis Sci 53:7754–7759
29. Grover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol 148:266–271